Docosahexaenoic Acid-Phosphatidylcholine Improves Cognitive Deficits in an Aβ23-35-Induced Alzheimer’s Disease Rat Model

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|16|5|558-564

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.16, Iss.5, 2016-02, pp. : 558-564

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Acetylpuerarin reduces inflammation and improves memory function in a rat model of Alzheimer's disease induced by Aβ_1-42

By Meng Q. H. Lou F. L. Hou W. X. Liu M. Guo H. Zhang X. M.

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 68, Iss. 11, 2013-11 ,pp. : 904-908

Govi-Verlag

Access to resources Recommend Favorite

The Effects of Soluble A&bgr; Oligomers on Neurodegeneration in Alzheimer's Disease

Current Pharmaceutical Design, Vol. 20, Iss. 15, 2014-05 ,pp. : 2506-2519

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmaceutical treatment for cognitive deficits in Alzheimer’s disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps

By Bartus Raymond Dean Reginald

Psychopharmacology, Vol. 202, Iss. 1-3, 2009-01 ,pp. : 15-36

Springer Publishing Company

Access to resources Recommend Favorite

Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer’s disease

By Van Dam Debby Coen Katrien De Deyn Peter

Psychopharmacology, Vol. 197, Iss. 1, 2008-03 ,pp. : 37-43

Springer Publishing Company

Access to resources Recommend Favorite

Transgenic animal model for Alzheimer’s disease

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 6, 1998-06 ,pp. : 729-732

Informa Healthcare

Access to resources Recommend Favorite